Histone deacetylases function as novel potential therapeutic targets for cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Hepatology Research

• Publication date

  2017-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/hepr.12757PMID 27457249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer

  2016cited by this paper
• Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression

  2016cited by this paper
• Effect of histone deacetylase on prostate carcinoma.

  2015cited by this paper
• Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.

  2015cited by this paper
• MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.

  2015cited by this paper
• Dynamic structures in DNA damage responses & cancer.

  2015cited by this paper
• A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells

  2015cited by this paper
• Epigenetic targets for novel therapies of lung diseases.

  2015cited by this paper
• Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.

  2015cited by this paper
• HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis

  2015cited by this paper
• Histone Deacetylase HDAC8 Promotes Insulin Resistance and β-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.

  2015cited by this paper
• Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma

  2015cited by this paper
• Histone deacetylases as therapeutic targets--from cancer to cardiac disease.

  2015cited by this paper
• Histone deacetylase inhibitors and cell death

  2014cited by this paper
• Dynamic Rearrangement of F-Actin Is Required to Maintain the Antitumor Effect of Trichostatin A

  2014cited by this paper
• The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma.

  2014cited by this paper
• Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.

  2014cited by this paper
• Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.

  2014cited by this paper
• Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.

  2014cited by this paper
• Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment

  2014cited by this paper
• Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1.

  2014cited by this paper
• Allele‐specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma

  2014cited by this paper
• Role of Bax/Bcl-2 family members in green tea polyphenol induced necroptosis of p53-deficient Hep3B cells

  2014cited by this paper
• Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

  2014cited by this paper
• Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax.

  2014cited by this paper
• Histone Deacetylase HDAC4 Promotes Gastric Cancer SGC-7901 Cells Progression via p21 Repression

  2014cited by this paper
• HDAC11 is a novel drug target in carcinomas

  2013cited by this paper
• MEF2 Is a Converging Hub for Histone Deacetylase 4 and Phosphatidylinositol 3-Kinase/Akt-Induced Transformation

  2013cited by this paper
• Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer

  2013cited by this paper
• HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?

  2013cited by this paper
• Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification.

  2013cited by this paper
• p53 as an intervention target for cancer and aging

  2013cited by this paper
• Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?

  2013cited by this paper
• Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.

  2013cited by this paper
• Specific Acetylation of p53 by HDAC Inhibition Prevents DNA Damage-Induced Apoptosis in Neurons

  2013cited by this paper
• Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression*

  2013cited by this paper
• The future of epigenetic therapy in solid tumours—lessons from the past

  2013cited by this paper
• Class I HDAC imaging using [3H]CI-994 autoradiography

  2013cited by this paper
• cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases.

  2013cited by this paper
• Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Sensitization of tumor cells by targeting histone deacetylases.

  2012cited by this paper
• Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.

  2012cited by this paper
• Functional genomic studies: insights into the pathogenesis of liver cancer.

  2012cited by this paper
• Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

  2012cited by this paper
• HDAC1 Inactivation Induces Mitotic Defect and Caspase-Independent Autophagic Cell Death in Liver Cancer

  2012cited by this paper
• Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8

  2012cited by this paper
• Epigenetics as a Therapeutic Target in Breast Cancer

  2012cited by this paper
• Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation.

  2012cited by this paper
• Histone deacetylase 6 functions as a tumor suppressor by activating c‐Jun NH2‐terminal kinase‐mediated beclin 1‐dependent autophagic cell death in liver cancer

  2012cited by this paper
• The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage.

  2012cited by this paper
• Targeted Inactivation of HDAC2 Restores p16INK4a Activity and Exerts Antitumor Effects on Human Gastric Cancer

  2012cited by this paper
• Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis.

  2012cited by this paper
• HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

  2012cited by this paper
• Cancer epigenetics reaches mainstream oncology

  2011cited by this paper
• The role of class I histone deacetylase (HDAC) on gluconeogenesis in liver.

  2011cited by this paper
• Sirtuins, Bioageing, and Cancer

  2011cited by this paper
• Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer.

  2011cited by this paper
• NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells.

  2011cited by this paper
• HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

  2011cited by this paper
• HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.

  2011cited by this paper
• Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.

  2011cited by this paper
• The impact of acetylation and deacetylation on the p53 pathway

  2011cited by this paper
• research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

  2010cited by this paper
• The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

  2010cited by this paper
• Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma

  2010cited by this paper
• Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.

  2010cited by this paper
• The many roles of histone deacetylases in development and physiology: implications for disease and therapy

  2009cited by this paper
• HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells.

  2009cited by this paper
• HDAC2: a critical factor in health and disease.

  2009cited by this paper
• Histone Deacetylase 8 in Neuroblastoma Tumorigenesis

  2009cited by this paper
• HDAC family: What are the cancer relevant targets?

  2009cited by this paper
• The critical role of the class III histone deacetylase SIRT1 in cancer.

  2009cited by this paper
• Targeting of HDAC8 and investigational inhibitors in neuroblastoma

  2009cited by this paper
• HDAC expression and clinical prognosis in human malignancies.

  2009cited by this paper
• Expression of Hypoxia-Inducible Factor-1&agr;, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic Carcinoma: Correlation With Poor Prognosis With Possible Regulation

  2008cited by this paper
• Developmental expression of histone deacetylase 11 in the murine brain

  2008cited by this paper
• Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

  2007cited by this paper
• Histone Deacetylase 7 Silencing Alters Endothelial Cell Migration, a Key Step in Angiogenesis

  2007cited by this paper
• Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation

  2007cited by this paper
• HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients.

  2007cited by this paper
• Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas.

  2007cited by this paper
• Histone deacetylases and cancer

  2007cited by this paper
• Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity.

  2007cited by this paper
• Epigenetics and airways disease

  2006cited by this paper
• Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours

  2006cited by this paper
• Crystal structure of a bacterial class 2 histone deacetylase homologue.

  2005cited by this paper
• Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

  2005cited by this paper
• Acetylation and deacetylation of non-histone proteins.

  2005cited by this paper
• Anaphylatoxin C3a receptors in asthma

  2005cited by this paper
• PI3K-Akt pathway: Its functions and alterations in human cancer

  2004cited by this paper
• Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

  2004cited by this paper
• Role of class I and class II histone deacetylases in carcinoma cells using siRNA.

  2003cited by this paper
• Histone Deacetylase 1/mSin3A Disrupts Gamma Interferon-Induced CIITA Function and Major Histocompatibility Complex Class II Enhanceosome Formation

  2003cited by this paper
• Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.

  2003cited by this paper
• Histone deacetylases (HDACs): characterization of the classical HDAC family.

  2003cited by this paper
• Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10*

  2002cited by this paper
• Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin.

  2001cited by this paper
• Histone acetylation in chromatin structure and transcription

  1997cited by this paper
• PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

  1997cited by this paper

• Microglial histone deacetylase-3 conditional deletion attenuates neurological deficits after intracerebral hemorrhage

  2026cites this paper
• The interplay between nutrigenomics and low-carbohydrate ketogenic diets in personalized healthcare

  2025cites this paper
• Mechanism and application of HDAC inhibitors in the treatment of hepatocellular carcinoma

  2025cites this paper
• Sulforaphane from broccoli, an epigenetic modulator in cancer cells

  2025cites this paper
• In-Silico profiling of new pyrazoline derivatives as histone deacetylase 2 and 6 inhibitors

  2025cites this paper
• Nutritional approaches in combating therapeutic resistance and enhancing treatment efficacy in cancer: the impact of ketogenic diets

  2025cites this paper
• Dissecting the epigenetic orchestra of HDAC isoforms in breast cancer development: a review

  2024cites this paper
• Inhibition of histone deacetylase 6 destabilizes ERK phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction

  2023cites this paper
• A Review on the Anticancer Activity of Carbazole-based Tricyclic Compounds.

  2023cites this paper
• Epigenetic drugs as new emerging therapeutics: What is the scale's orientation of application and challenges?

  2023cites this paper
• Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials

  2023cites this paper
• The role of Ca2+-signaling in the regulation of epigenetic mechanisms.

  2023cites this paper
• Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)

  2023cites this paper
• Knockdown of sirtuin6 positively regulates acetylation of DNMT1 to inhibit the NOTCH signaling pathway in non-small cell lung cancer cell lines.

  2023cites this paper
• Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials

  2023cites this paper
• HDAC inhibitors: Promising agents for leukemia treatment.

  2023cites this paper
• MiR-589-5p Inhibits Cell Proliferation by Targeting Histone Deacetylase 3 in Triple Negative Breast Cancer.

  2022cites this paper
• Effect of valproic acid on extrinsic and intrinsic apoptotic pathways, cell viability and apoptosis in hepatocellular carcinoma PLC/PRF5 cell line.

  2022cites this paper
• Effect of histone deacetylase 8 gene deletion on breast cancer cellular mechanism in vitro and in vivo study.

  2022cites this paper
• Transcription suppression is mediated by the HDAC1–Sin3 complex in Xenopus nucleoplasmic extract

  2022cites this paper
• Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies

  2022cites this paper
• Comprehensive Analysis of Histone Modifications in Hepatocellular Carcinoma Reveals Different Subtypes and Key Prognostic Models

  2022cites this paper
• Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option

  2022cites this paper
• Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy

  2022cites this paper
• Role of ANO1 in tumors and tumor immunity

  2022cites this paper
• Suppression of histone deacetylase 1 by JSL-1 attenuates the progression and metastasis of cholangiocarcinoma via the TPX2/Snail axis

  2022cites this paper
• Recent Developments on Synthesis Strategies, SAR Studies and Biological Activities of β-Carboline Derivatives – An Update

  2022cites this paper
• An activatable and tumor-targeting NIR fluorescent probe for imaging of histone deacetylase 6 in cancer cells and in vivo.

  2022cites this paper
• Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer.

  2021cites this paper
• The clinical significance of histone deacetylase-8 in human breast cancer.

  2021cites this paper
• Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models

  2021cites this paper
• Strategies of Cell Signaling and Critical Focus on Etiology of Hepatocellular Carcinoma

  2021cites this paper
• Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma

  2021cites this paper
• β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies.

  2021cites this paper
• Pharmacotherapy for SARS-CoV-2 and Seizures for drug repurposing presumed on Mechanistic Targets.

  2021cites this paper
• Studying Histone Deacetylase Inhibition and Apoptosis Induction of Psammaplin A Monomers with Modified Thiol Group.

  2021cites this paper
• Identification of unique subtype-specific interaction features in Class II zinc-dependent HDAC subtype binding pockets: A computational study

  2021cites this paper
• Ketogenic Diet in Cancer Prevention and Therapy: Molecular Targets and Therapeutic Opportunities

  2021cites this paper
• Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis.

  2021cites this paper
• Fluorescent Nanohybrids from ZnS/CdSe Quantum Dots Functionalized with Triantennary, N-Hydroxy-p-(4-arylbutanamido)benzamide/Gallamide Dendrons That Act as Inhibitors of Histone Deacetylase for Lung Cancer.

  2021cites this paper
• 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression

  2020cites this paper
• Zinc dependent Histone deacetylase inhibitors in cancer therapeutics: Recent update.

  2020cites this paper
• HDAC Overexpression in a NUT Midline Carcinoma of the Parotid Gland with Exceptional Survival: A Case Report

  2020cites this paper
• Romidepsin (FK228), An Histone Deacetylase Inhibitor, and its Analogues in Cancer Chemotherapy.

  2020cites this paper
• Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells

  2020cites this paper
• Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group

  2020cites this paper
• Identification of lysine acetylome in cervical cancer by label-free quantitative proteomics

  2020cites this paper
• PAICS contributes to gastric carcinogenesis and participates in DNA damage response by interacting with histone deacetylase 1/2

  2020cites this paper
• Chidamide acts on the histone deacetylase‐mediated miR‐34a/Bcl‐2 axis to regulate NB4 cell line proliferation and apoptosis

  2020cites this paper
• Identification of key genes and important histone modifications in hepatocellular carcinoma

  2020cites this paper
• HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target

  2020cites this paper
• Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach

  2020cites this paper
• Histone Deacetylase Inhibitors and Papillary Thyroid Cancer.

  2020cites this paper
• Role of androgen receptor splice variants, their clinical relevance and treatment options

  2019cites this paper
• Combination of Pan-HDAC Inhibitor and COX-2 Inhibitor Produces Synergistic Anticancer Effects in Human Salivary Adenoid Cystic Cancer Cells.

  2019cites this paper
• MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression.

  2019cites this paper
• An overview of epigenetic agents and natural nutrition products targeting DNA methyltransferase, histone deacetylases and microRNAs.

  2019cites this paper
• HDAC inhibitors induce proline dehydrogenase (POX) transcription and anti-apoptotic autophagy in triple negative breast cancer.

  2019cites this paper
• Recent advances in class IIa histone deacetylases research.

  2019cites this paper
• Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies

  2019cites this paper
• H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy

  2019cites this paper
• Effect of Histone Deacetylase Inhibition on Ovarian Cancer Cell Survival

  2019cites this paper
• Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70

  2019cites this paper
• Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas

  2019cites this paper
• Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.

  2019cites this paper
• Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells

  2019cites this paper
• An in-line capillary electrophoresis assay for the high-throughput screening of histone deacetylase inhibitors.

  2019cites this paper
• Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.

  2018cites this paper
• miR-216b-5p is Down-Regulated in Human Breast Cancer and Inhibits Proliferation and Progression by Targeting HDAC8 Oncogene

  2018cites this paper
• Ras-ERK1/2 signaling contributes to the development of colorectal cancer via regulating H3K9ac

  2018cites this paper
• Translocations involving ETS family proteins in human cancer.

  2018cites this paper
• Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.

  2018cites this paper
• Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells

  2018cites this paper
• Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU.

  2018cites this paper
• Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway

  2018cites this paper
• Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells.

  2018cites this paper
• Valproic acid attenuates manganese‐induced reduction in expression of GLT‐1 and GLAST with concomitant changes in murine dopaminergic neurotoxicity

  2018cites this paper
• Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.

  2018cites this paper
• Histone deacetylases (HDACs) as therapeutic target for depressive disorders

  2018cites this paper
• Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.

  2018cites this paper
• Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK

  2017cites this paper
• Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.

  2017cites this paper
• Anti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivo

  2017cites this paper
• Acetylation and deacetylation in cancer stem-like cells

  2017cites this paper
• Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor

  2017cites this paper
• Cell-specific mechanisms of TMEM16A Ca2+-activated chloride channel in cancer

  2017cites this paper
• Acetylation and deacetylation in cancer stem-like cells.

  2017cites this paper
• Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges

  2017cites this paper
• Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN

  2017cites this paper
• [Protective effect of histone acetylation against cortical injury in neonatal rats].

  2017cites this paper
• c-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia

  2016cites this paper